Paracox

Indications

• Treatment of gastrointestinal nematodes in livestock
• Control of parasitic infections in ruminants
• Support for livestock health and productivity

Dosage

Children: Refer to veterinary guidelines for pediatric dosing, as it may vary based on the age and weight of the young animals.

Adults: Refer to veterinary guidelines for specific dosing information based on the type of livestock and severity of infection.

Mechanism of action

Acervulina acts by interfering with the energy metabolism of nematodes, specifically targeting the mitochondrial function of the parasites. This disruption leads to a depletion of ATP, which is essential for the survival and reproduction of the worms. The drug may also affect the neuromuscular coordination of the parasites, leading to paralysis and eventual death.

Pharmacodynamics

The pharmacodynamic properties of Acervulina include its ability to bind to specific receptors in the parasite's neuromuscular system, effectively causing paralysis. The onset of action is typically rapid, with significant effects observed within hours of administration. The drug's efficacy is influenced by the life cycle stage of the target parasites, with the greatest impact seen in the adult forms.

Pharmacokinetics

Acervulina is absorbed following oral administration, with peak plasma concentrations occurring within a few hours. The drug is metabolized primarily in the liver, and its metabolites are excreted mainly via the urine. The half-life of Acervulina varies depending on the species of the animal, but it generally has a moderate duration of action, necessitating repeat dosing for sustained effects.

Pregnancy

Safety in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether acervulina is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Dosage

Children: Refer to established pediatric dosing guidelines for appropriate dosing.

Adults: Refer to established pharmacological guidelines for appropriate dosing.

Pregnancy

Data on the use of brunetti during pregnancy is limited. Consult a healthcare provider for guidance.

Breast-feeding

It is unknown whether brunetti is excreted in human milk. Caution is advised when administering to breastfeeding women.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Dosage

Children: Refer to the BNF for Children for appropriate pediatric dosing guidance.

Adults: Refer to the relevant drug monograph or clinical guidelines for adult dosing information.

Mechanism of action

Doses work through various mechanisms depending on the specific drug class it belongs to. Generally, this may involve receptor binding, inhibition of enzyme activity, or modulation of ion channels, leading to therapeutic effects in the body. Key pathways may include neurotransmitter modulation, hormonal regulation, or alteration of cellular signaling cascades.

Pharmacodynamics

The pharmacodynamics of doses involves the relationship between drug concentration and its pharmacological effect. This can include agonistic or antagonistic actions at specific receptors, modulation of metabolic pathways, or effects on physiological systems. The therapeutic window, efficacy, and potential side effects are integral to understanding how doses impact clinical outcomes.

Pharmacokinetics

Pharmacokinetics refers to the absorption, distribution, metabolism, and excretion (ADME) of doses. Factors such as bioavailability, half-life, volume of distribution, and clearance rates play a critical role in determining the appropriate dosing regimen for patients. Variability in these parameters can occur based on individual patient characteristics, including age, kidney and liver function, and concomitant medications.

Pregnancy

Refer to relevant guidelines and consult a healthcare professional for specific advice regarding use during pregnancy.

Breast-feeding

Consult a healthcare professional as the safety during breastfeeding may vary based on the drug.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Indications

• Coccidiosis in livestock
• Coccidiosis in poultry
• Prevention of coccidiosis in young animals

Dosage

Children: Refer to specific veterinary guidelines for dosing information based on the type of anticoccidial agent used and the species being treated.

Adults: Refer to specific veterinary guidelines for dosing information based on the type of anticoccidial agent used and the species being treated.

Mechanism of action

Eimeria invades the epithelial cells of the intestinal lining, leading to cellular destruction and inflammation. The host's immune response to the infection can cause further tissue damage. The specific mechanisms by which Eimeria causes disease include the disruption of intestinal integrity, malabsorption of nutrients, and the induction of diarrhea, which can result in dehydration and secondary infections.

Pharmacodynamics

Pharmacodynamics of agents that target Eimeria typically involve the inhibition of the parasite's life cycle, reducing oocyst shedding and preventing replication within the host. Anticoccidial drugs such as ionophores or sulfonamides disrupt essential metabolic processes in the parasite, leading to its death and alleviation of clinical symptoms in the host.

Pharmacokinetics

The pharmacokinetics of anticoccidial drugs vary depending on the specific agent used. Generally, these drugs are administered orally and are absorbed through the gastrointestinal tract. They may undergo hepatic metabolism and are excreted primarily through the feces. The half-life and bioavailability can differ based on the formulation and the host species, necessitating careful management and dosing based on veterinary guidance.

Pregnancy

Eimeria infections are not typically a concern in pregnancy; however, specific treatment should be assessed based on the type of Eimeria species and the patient's condition.

Breast-feeding

There is limited information on the effects of Eimeria on breastfeeding; consult with a healthcare provider for tailored advice.

Storage

Store in a cool, dry place away from direct sunlight. Ensure formulations are kept out of reach of children.

Indications

• Osteoarthritis
• Rheumatoid arthritis
• Acute musculoskeletal pain
• Chronic pain conditions

Dosage

Children: Refer to the specific product guidelines for dosing information, as it can vary based on condition and formulation.

Adults: Refer to the specific product guidelines for dosing information, as it can vary based on condition and formulation.

Mechanism of action

Maxima acts by inhibiting the synthesis of prostaglandins through the inhibition of cyclooxygenase (COX) enzymes, particularly COX-2. This action reduces the inflammatory response and alleviates pain. Additionally, it may exert effects on other inflammatory mediators, contributing to its overall therapeutic effects.

Pharmacodynamics

Maxima displays a dose-dependent analgesic effect, providing relief from moderate to severe pain. Its anti-inflammatory action helps decrease swelling and tenderness in affected tissues. The onset of action typically occurs within hours, with peak effects seen within a few days of consistent use.

Pharmacokinetics

Maxima is well absorbed after oral administration, with peak plasma concentrations reached within a few hours. It is extensively metabolized in the liver, primarily via conjugation. The elimination half-life varies, but metabolites are excreted mainly through the kidneys. This pharmacokinetic profile necessitates caution in patients with hepatic or renal impairment.

Pregnancy

Consult healthcare provider. Insufficient data on safety during pregnancy.

Breast-feeding

Consult healthcare provider. Limited data on excretion in breast milk.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Dosage

Children: Refer to specific guidelines or clinical references for appropriate dosing information.

Adults: Refer to specific guidelines or clinical references for appropriate dosing information.

Pregnancy

There is limited data on the safety of mitis during pregnancy. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Limited data on the excretion of mitis in breast milk. Caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Indications

• Ascariasis
• Enterobiasis (pinworm infection)
• Hookworm infection
• Strongyloidiasis
• Taeniasis (tapeworm infection)
• Other helminthic infections

Dosage

Children: Refer to the BNF for Children for appropriate dosing in paediatric patients, as it is dependent on age and weight.

Adults: Refer to the specific BNF or clinical guidelines for adult dosing, as it may vary based on the type of infection and severity.

Mechanism of action

Necatrix acts primarily by inhibiting the synthesis of microtubules in the parasite, which interferes with their ability to absorb glucose and other nutrients. This leads to depletion of glycogen stores and ultimately results in death of the parasite. Additionally, necatrix may induce paralysis in the worms, facilitating their expulsion from the gastrointestinal tract.

Pharmacodynamics

The pharmacodynamics of necatrix involve its action on the parasitic cells, where it disrupts the normal cellular function and metabolism. The drug's ability to interfere with glucose uptake is crucial, as it deprives the parasites of energy, leading to their death. Its effects are generally observed within days of administration, depending on the type and load of the infection.

Pharmacokinetics

Necatrix is generally well-absorbed after oral administration, with peak plasma concentrations occurring within a few hours. The drug is metabolized in the liver and its metabolites are excreted primarily via the kidneys. The elimination half-life varies but is typically within a range that allows for once-daily dosing in most cases. Its safety profile is well established, with minimal adverse effects when used as directed.

Pregnancy

There is limited data on the safety of necatrix during pregnancy. It is advisable to avoid use unless clearly needed and prescribed by a healthcare professional.

Breast-feeding

Caution is advised when using necatrix during breastfeeding due to insufficient information on excretion in breast milk.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Indications

• Cryptosporidiosis
• Giardiasis
• Gastroenteritis caused by protozoan parasites

Dosage

Children: Specific dosing information is not applicable as oocysts are a form of the parasite rather than a medication. Treatment typically involves antiparasitic agents as indicated in clinical practice.

Adults: Specific dosing information is not applicable as oocysts are a form of the parasite rather than a medication. Treatment typically involves antiparasitic agents as indicated in clinical practice.

Mechanism of action

Oocysts themselves do not have a direct pharmacological action. Instead, they serve as a protective cystic stage for protozoan parasites that can infect host organisms. Once ingested, the oocysts release sporozoites in the intestines, which invade intestinal epithelial cells, leading to infection and disease.

Pharmacodynamics

Since oocysts are not drugs, they do not have pharmacodynamic properties. However, the parasites that emerge from the oocysts can disrupt normal intestinal function, leading to malabsorption, inflammation, and symptoms associated with gastrointestinal infections.

Pharmacokinetics

Oocysts are not absorbed or metabolized in the human body like traditional medications. After ingestion, they pass through the gastrointestinal tract where they can remain viable, eventually leading to the release of infectious sporozoites. The duration of infection and subsequent symptoms can vary based on the host's immune response and the specific parasite involved.

Pregnancy

Oocysts, particularly those from pathogens like Cryptosporidium or Giardia, may pose risks during pregnancy due to potential infections. It is advisable for pregnant individuals to avoid exposure.

Breast-feeding

The presence of oocysts in breast milk can be a concern if the mother is infected with pathogens. It is recommended to consult healthcare providers regarding breastfeeding if oocyst infection is suspected.

Storage

Oocysts should be stored in a cool, dry place if collected for laboratory analysis, away from sunlight and moisture to prevent degradation.

Indications

• Schizophrenia
• Bipolar disorder
• Severe anxiety
• Agitation
• Nausea and vomiting
• Intractable hiccups
• Preoperative sedation

Dosage

Adults: Refer to clinical guidelines for individual dosing based on the condition being treated, starting doses may vary widely, and titration is typically based on clinical response and tolerability.

Mechanism of action

Chlorpromazine exerts its antipsychotic effects primarily by antagonizing dopamine D2 receptors in the central nervous system. This blockade leads to a decrease in dopaminergic transmission, which is linked to the positive symptoms of schizophrenia, such as hallucinations and delusions. Additionally, chlorpromazine has antagonistic effects on other neurotransmitter receptors, including serotonin (5-HT2A), histamine (H1), and alpha-adrenergic receptors, contributing to its overall therapeutic profile.

Pharmacodynamics

Chlorpromazine exhibits a dose-dependent relationship where higher doses may yield greater efficacy in managing psychotic symptoms, but also increase the risk of side effects. Common side effects include sedation, extrapyramidal symptoms, and anticholinergic effects. Its sedative properties can be beneficial in treating acute agitation but may limit its use in certain patient populations. The drug's effects on the autonomic nervous system can also lead to orthostatic hypotension and weight gain.

Pharmacokinetics

Chlorpromazine is well-absorbed following oral administration, with peak plasma concentrations occurring approximately 2 to 4 hours post-dose. It undergoes extensive hepatic metabolism, primarily via cytochrome P450 enzymes, leading to various active metabolites. The elimination half-life ranges from 30 to 50 hours, allowing for once or twice daily dosing in most cases. Chlorpromazine is highly protein-bound, mainly to albumin, and has a large volume of distribution, indicating extensive tissue uptake.

Pregnancy

The safety of praecox during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

There is insufficient data on the excretion of praecox in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Indications

• Coccidiosis in poultry
• Gastrointestinal infection caused by protozoan parasites
• Prevention of coccidiosis in livestock

Dosage

Children: Refer to specific product guidelines, as dosages can vary based on the agent used and the severity of the infection.

Adults: Refer to specific product guidelines, as dosages can vary based on the agent used and the severity of the infection.

Mechanism of action

Tenella, as a protozoan, does not have a defined pharmacological mechanism of action like traditional drugs. However, medications used against coccidiosis typically work by disrupting the life cycle of the parasite, inhibiting its ability to reproduce, or targeting its metabolism. Common classes of drugs include ionophores, sulfonamides, and amprolium, which interfere with different metabolic pathways critical for the parasite's survival.

Pharmacodynamics

The pharmacodynamics of drugs used to treat infections caused by tenella revolve around their ability to inhibit the growth and reproduction of the parasite. For instance, ionophores alter the ion transport across the cell membrane, leading to cellular dysfunction in the parasite. Sulfonamides inhibit folate synthesis, essential for nucleic acid production, thereby preventing the growth of rapidly dividing protozoan cells.

Pharmacokinetics

The pharmacokinetics of drugs used to treat tenella infections vary depending on the specific agent. Generally, these drugs are absorbed in the gastrointestinal tract, with metabolism occurring in the liver. Excretion is primarily via urine or feces. The rate of absorption and elimination can be affected by factors such as the animal's age, health status, and the presence of food in the stomach.

Pregnancy

Safety in pregnancy has not been established. Use only if potential benefit justifies potential risk to the fetus.

Breast-feeding

Caution is advised; excretion in human milk is unknown. Weigh the risks and benefits before use.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.